The 13D Report
The 13D Report
Shareholder activism
⌘K
Signup free
activistletters

Wynnefield Capital (7%) Launches Proxy Fight at TechPrecision (TPCS), Slams M&A Debacles, Governance Failures, and Value Destruction

Summary

Wynnefield Capital, a 7% holder of TechPrecision, is urging shareholders to back its nominees, General Victor Renuart (Ret.) and Robert Straus, on the BLUE proxy card, citing years of poor performance, failed M&A, governance lapses, weak oversight, and lack of transparency. It argues the current Board has destroyed value and lost credibility, while its nominees bring proven leadership, governance, and shareholder alignment to restore accountability and unlock value

Company Name: TECHPRECISION CORP
Symbol: TPCS
Filing Date: Nov-22-2024
Filer Name: WYNNEFIELD PARTNERS SMALL CAP VALUE LP I

Download Presentation
Wynnefield-Nov-22-2024.pdf
5 MB
download-circle

Source: https://www.sec.gov/Archives/edgar/data/1251565/000110465924122021/tm2429197d1_dfan14a.htm

Member discussion

More like this

STAAR Surgical (STAA): Broadwood Partners Urges Shareholders to Reject Alcon Merger Over Governance and Valuation Concerns

Summary Broadwood Partners’ presentation argues that STAAR Surgical’s sale to Alcon is ill-timed, flawed, and undervalued. It claims STAAR’

Khrom Capital Pushes Acadia Healthcare (ACHC) Board to Pursue Sale, Slams Entrenched Leadership and Poor Capital Allocation

Summary Khrom Capital, owning 5.5% of Acadia Healthcare, criticized the company’s decade-long underperformance, poor capital allocation, and entrenched

STAAR Surgical (STAA): Broadwood Capital Urges Shareholders to Reject Alcon Merger, Highlighting Governance Conflicts and Poor Timing

Summary Broadwood Capital, owning 27.5% of STAAR Surgical, urged shareholders to vote against the proposed $28-per-share sale to Alcon,

Al Hartman Presses Silver Star Properties REIT (SLVS) Holders: Reject Current Board, Back Liquidation Plan Amid Alleged Misconduct and Value Destruction

Summary Al Hartman’s Hartman Shareholder Alliance urges Silver Star investors to vote the BLUE proxy as a “last chance”

Broadwood Partners Challenges STAAR Surgical (STAA) Sale to Alcon, Citing Inopportune Timing, Governance Issues, and Undervaluation

Summary Broadwood Partners, STAAR Surgical’s largest shareholder with a 27.5% stake, urged stockholders to vote against the proposed

Yunqi Capital Challenges STAAR Surgical (STAA)–Alcon Deal, Citing Undervaluation, Weak China Outlook Assumptions, and Governance Failures

Summary Yunqi Capital, a 5.1% shareholder of STAAR Surgical, announced it will vote against the company’s proposed $28